12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ganitumab: Phase III discontinued

Amgen and Takeda stopped the double-blind, placebo-controlled, international Phase III GAMMA trial in patients with metastatic adenocarcinoma of the pancreas after an interim analysis by an independent DMC showed that first-line treatment with ganitumab plus gemcitabine was unlikely to meet the primary endpoint of OS vs. gemcitabine alone. No safety concerns were...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >